ISTA Pharmaceuticals releases preliminary results from phase II/III study of bepotastine

ISTA Pharmaceuticals Inc. announced results from the preliminary analysis of its phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily.

Related Videos

Related Content

Advertisement

March 18th 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 18th 2025

FDA approves expanded label for fluocinolone acetonide intravitreal implant

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 18th 2025

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

March 17th 2025

Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE

Related Content

Advertisement

March 18th 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 18th 2025

FDA approves expanded label for fluocinolone acetonide intravitreal implant

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 18th 2025

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

March 17th 2025

Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE